Functional Cure as a New Concept of Therapy for Multiple Myeloma

Multiple myeloma (MM) is a genetically complex and clinically heterogeneous disease which has been traditionally considered incurable. In the light of new drugs and rising diagnostic potential, more and more attention is being given to a new concept of MM therapy known as “functional cure”. One of its definitions is “the sustaining absence of measurable disease for 5 years or more upon chemotherapy withdrawal with a satisfactory quality of life being maintained”. The present review focuses on the key aspects of MM diagnosis and treatment with the use of the IMWG SLiM-CRAB criteria for identifying asymptomatic patients with high risk for progression within the next 2 years. Special attention is paid to current data for verification of smoldering multiple myeloma (SMM) with high risk for early transformation to symptomatic MM. This review discusses two treatment strategies for high-risk SMM patients including low-intensity therapy options aimed at prolonging the time to progression and intensified therapy aimed at eradicating minimal residual disease (MRD) and achieving possible cure. For newly diagnosed MM patients who are eligible for autologous hematopoietic stem cell transplantation (auto-HSCT), the priority options are induction protocols with 4 active drugs (D-VRd and Isa-VRd) with subsequent auto-HSCT and maintenance therapy. This approach yields durable MRD-negative response in many patients — evidence suggesting that they can achieve functional cure in the long term. In auto-HSCT-ineligible patients, the preferred option is combined therapy with anti-CD38 monoclonal antibodies (daratumumab and isatuximab) showing good results in achieving MRD-negativity and better survival rates. Prospects for MM treatment are bound up with the development of immunotherapy (CAR-T cells and bispecific antibodies) which has proven to be highly effective in refractory MM patients. New treatment methods for newly diagnosed MM open up expanded possibilities of achieving functional cure in a considerable part of patients. Functional cure is becoming a realistic goal of MM therapy, which clearly indicates the need for further studies and development of personalized treatment approaches.

• Sergei Vyacheslavovich Semochkin PA Gertsen Moscow Oncology Research Institute, branch of the NMRC of Radiology, 3 2-i Botkinskii pr-d, Moscow, Russian Federation, 125284 ; NI Pirogov Russian National Research Medical University, 1 Ostrovityanova ul., Moscow, Russian Federation, 117997 https://orcid.org/0000-0002-8129-8114 (unauthenticated)

1. Семочкин С.В. Множественная миелома. Клиническая онкогематология. 2020;13(1):1–24. [Semochkin S.V. Multiple myeloma. Clinical oncohematology. 2020;13(1):1–24. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2020-13-1-1-24
2. Paiva P, Vidriales MB, Puig N, et al. What Is the Frequency of Transplant-Eligible Multiple Myeloma Patients Being Cured? The Impact of an MGUS-like Signature at Diagnosis and MRD-Negativity. Blood. 2015;126(23):725. doi: 10.1182/blood.V126.23.725.725. DOI: https://doi.org/10.1182/blood.V126.23.725.725
3. Santucci C, Carioli G, Bertuccio P, et al. Progress in cancer mortality, incidence, and survival: a global overview. Eur J Cancer Prev. 2020;29(5):367–81. doi: 10.1097/CEJ.0000000000000594. DOI: https://doi.org/10.1097/CEJ.0000000000000594
4. Аршанская Е.Г., Семочкин С.В., Румянцев А.Г. Качество жизни подростков и молодых взрослых с длительными ремиссиями лимфомы. Клиническая онкогематология. 2014;7(2):184–91. [Arshanskaya E.G., Semochkin S.V., Rumyantsev A.G. Quality of life in adolescent and young adult Hodgkin’s lymphoma survivors. Clinical oncohematology. 2014;7(2):184–91. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2014-7-2-184-191
5. Engelhardt M, Kortüm KM, Goldschmidt H, Merz M. Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible. Haematologica. 2024;109(8):2420–35. doi: 10.3324/haematol.2023.283058. DOI: https://doi.org/10.3324/haematol.2023.283058
6. Mohty M, Avet-Loiseau H, Harousseau JL. Requirements for operational cure in multiple myeloma. Blood. 2021;138(16):1406–11. doi: 10.1182/blood.2021012854. DOI: https://doi.org/10.1182/blood.2021012854
7. Blokhin N, Larionov L, Perevodchikova N, et al. Clinical experiences with sarcolysin in neoplastic diseases. Ann N Y Acad Sci. 1958;68(3):1128–32. doi: 10.1111/j.1749-6632.1958.tb42675.x. DOI: https://doi.org/10.1111/j.1749-6632.1958.tb42675.x
8. Barlogie B, Hall R, Zander A, et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986;67(5):1298–301. DOI: https://doi.org/10.1182/blood.V67.5.1298.1298
9. Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802–24. doi: 10.1002/ajh.27422. DOI: https://doi.org/10.1002/ajh.27422
10. Usmani SZ, Hoering A, Cavo M, et al. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma – an IMWG Research Project. Blood Cancer J. 2018;8(12):123. doi: 10.1038/s41408-018-0155-7. DOI: https://doi.org/10.1038/s41408-018-0155-7
11. San-Miguel J, Avet-Loiseau H, Paiva B, et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022;139(4):492–501. doi: 10.1182/blood.2020010439. DOI: https://doi.org/10.1182/blood.2020010439
12. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–е548. doi: 10.1016/S1470-2045(14)70442-5. DOI: https://doi.org/10.1016/S1470-2045(14)70442-5
13. Abdallah NH, Lakshman A, Kumar SK, et al. Mode of progression in smoldering multiple myeloma: a study of 406 patients. Blood Cancer J. 2024;14(1):9. doi: 10.1038/s41408-024-00980-5. DOI: https://doi.org/10.1038/s41408-024-00980-5
14. Pérez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110(7):2586–92. doi: 10.1182/blood-2007-05-088443. DOI: https://doi.org/10.1182/blood-2007-05-088443
15. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111(2):785–9. doi: 10.1182/blood-2007-08-108357. DOI: https://doi.org/10.1182/blood-2007-08-108357
16. Dhodapkar MV, Sexton R, Waheed S, et al. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood. 2014;123(1):78–85. doi: 10.1182/blood-2013-07-515239. DOI: https://doi.org/10.1182/blood-2013-07-515239
17. Lakshman A, Rajkumar SV, Buadi FK, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8(6):59. doi: 10.1038/s41408-018-0077-4. DOI: https://doi.org/10.1038/s41408-018-0077-4
18. Mateos MV, Kumar S, Dimopoulos MA, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10(10):102. doi: 10.1038/s41408-020-00366-3. DOI: https://doi.org/10.1038/s41408-020-00366-3
19. Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582–90. doi: 10.1056/NEJMoa070389. DOI: https://doi.org/10.1056/NEJMoa070389
20. Schmidt T, Gahvari Z, Callander NS. SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2024;24(10):653–64. doi: 10.1016/j.clml.2024.03.008. DOI: https://doi.org/10.1016/j.clml.2024.03.008
21. Rajkumar SV, Kumar S, Lonial S, Mateos MV. Smoldering multiple myeloma current treatment algorithms. Blood Cancer J. 2022;12(9):129. doi: 10.1038/s41408-022-00719-0. DOI: https://doi.org/10.1038/s41408-022-00719-0
22. Wennmann M, Hielscher T, Kintzelé L, et al. Spatial Distribution of Focal Lesions in Whole-Body MRI and Influence of MRI Protocol on Staging in Patients with Smoldering Multiple Myeloma According to the New SLiM-CRAB-Criteria. Cancers (Basel). 2020;12(9):2537. doi: 10.3390/cancers12092537. DOI: https://doi.org/10.3390/cancers12092537
23. Ojo AS, Akinyemi O, Araoye MO, Ali A. Early Intervention With a Curative Intent Through an Intensive Therapy Versus Immunologic Disease Control Using a Minimal Intensity Approach in the Management of High-risk Smoldering Multiple Myeloma: A Systematic Review of Evidence From Clinical Trials. Clin Lymphoma Myeloma Leuk. 2023;23(1):e27–e40. doi: 10.1016/j.clml.2022.10.009. DOI: https://doi.org/10.1016/j.clml.2022.10.009
24. Multiple Myeloma. NCCN Guidelines Version 1.2025. Available from: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf (accessed 13.02.2025).
25. Vaxman I, Gertz MA. How I approach smoldering multiple myeloma. Blood. 2022;140(8):828–38. doi: 10.1182/blood.2021011670. DOI: https://doi.org/10.1182/blood.2021011670
26. Клинические рекомендации «Множественная миелома». 2024 (электронный документ). Доступно по: https://cr.minzdrav.gov.ru/preview-cr/144_2. Ссылка активна на 17.02.2025. [Clinical guidelines on multiple myeloma. 2024 (Internet). Available from: https://cr.minzdrav.gov.ru/preview-cr/144_2. Accessed 17.02.2025. (In Russ)]
27. Mateos MV, Hernández MT, Giraldo P, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17(8):1127–36. doi: 10.1016/S1470-2045(16)30124-3. DOI: https://doi.org/10.1016/S1470-2045(16)30124-3
28. Lonial S, Jacobus S, Fonseca R, et al. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. J Clin Oncol. 2020;38(11):1126–37. doi: 10.1200/JCO.19.01740. DOI: https://doi.org/10.1200/JCO.19.01740
29. Landgren CO, Chari A, Cohen YC, et al. Efficacy and Safety of Daratumumab in Intermediate/High-risk Smoldering Multiple Myeloma: Final Analysis of CENTAURUS. Blood. 2024:blood.2024025897. doi: 10.1182/blood.2024025897. Epub ahead of print. DOI: https://doi.org/10.1182/blood.2024025897
30. Dimopoulos MA, Voorhees PM, Schjesvold F, et al. Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma. N Engl J Med. 2024. doi: 10.1056/NEJMoa2409029. Epub ahead of print. DOI: https://doi.org/10.1056/NEJMoa2409029
31. Mateos MV, San-Miguel JF, Martinez-Lopez J, et al. Curative strategy (GEM-CESAR) for high-risk smoldering myeloma: Post-hoc analysis of sustained undetectable measurable residual disease. 2022 ASH Annual Meeting and Exposition. Blood. 2022;140(Suppl 1):292–4. doi: 10.1182/blood-2022-159606. DOI: https://doi.org/10.1182/blood-2022-159606
32. Kumar S, Alsina M, LaPlant B, et al. Fixed duration therapy with daratumumab, carfilzomib, lenalidomide and dexamethasone for high-risk smoldering multiple myeloma: Results of the ASCENT trial. 2022 ASH Annual Meeting and Exposition. Blood. 2022;140(Suppl 1):1830–2. doi: 10.1182/blood-2022-168930. DOI: https://doi.org/10.1182/blood-2022-168930
33. Hjorth M, Hellquist L, Holmberg E, et al. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I—a randomized study. Myeloma Group of Western Sweden. Eur J Haematol. 1993;50(2):95–102. doi: 10.1111/j.1600-0609.1993.tb00148.x. DOI: https://doi.org/10.1111/j.1600-0609.1993.tb00148.x
34. D’Arena G, Gobbi PG, Broglia C, et al. Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leuk Lymphoma. 2011;52(5):771–5. doi: 10.3109/10428194.2011.553000. DOI: https://doi.org/10.3109/10428194.2011.553000
35. Musto P, Petrucci MT, Bringhen S, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer. 2008;113(7):1588–95. doi: 10.1002/cncr.23783. DOI: https://doi.org/10.1002/cncr.23783
36. Mouhieddine TH. How to Identify and Manage High-Risk Smoldering Multiple Myeloma. Curr Oncol Rep. 2024;26(11):1398–409. doi: 10.1007/s11912-024-01596-5. DOI: https://doi.org/10.1007/s11912-024-01596-5
37. Yang Y, Zhao B, Lan H, et al. Bortezomib-induced peripheral neuropathy: Clinical features, molecular basis, and therapeutic approach. Crit Rev Oncol Hematol. 2024;197:104353. doi: 10.1016/j.critrevonc.2024.104353. DOI: https://doi.org/10.1016/j.critrevonc.2024.104353
38. Семочкин С.В. Механизмы действия противоопухолевых иммуномодуляторов — от тератогенности к терапии множественной миеломы. Гематология и трансфузиология. 2022;67(2):240–60. doi: 10.35754/0234-5730-2022-67-2-240-260. [Semochkin S.V. Mechanisms of action of immunomodulatory drugs — from teratogenicity to treatment of multiple myeloma. Russian journal of hematology and transfusiology. 2022;67(2):240–60. doi: 10.35754/0234-5730-2022-67-2-240-260. (In Russ)] DOI: https://doi.org/10.35754/0234-5730-2022-67-2-240-260
39. Andreozzi F, Dragani M, Quivoron C, et al. Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 Study. Cancers (Basel). 2023;15(5):1508. doi: 10.3390/cancers15051508. DOI: https://doi.org/10.3390/cancers15051508
40. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–20. doi: 10.1200/JCO.2005.04.242. DOI: https://doi.org/10.1200/JCO.2005.04.242
41. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863–9. doi: 10.1200/JCO.2015.61.2267. DOI: https://doi.org/10.1200/JCO.2015.61.2267
42. Dispenzieri A. Myeloma: management of the newly diagnosed high-risk patient. Hematology Am Soc Hematol Educ Program. 2016;2016(1):485–94. doi: 10.1182/asheducation-2016.1.485. DOI: https://doi.org/10.1182/asheducation-2016.1.485
43. D’Agostino M, Cairns DA, Lahuerta JJ, et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol. 2022;40(29):3406–18. doi: 10.1200/JCO.21.02614. DOI: https://doi.org/10.1200/JCO.22.02228
44. Clarke SE, Fuller KA, Erber WN. Chromosomal defects in multiple myeloma. Blood Rev. 2024;64:101168. doi: 10.1016/j.blre.2024.101168. DOI: https://doi.org/10.1016/j.blre.2024.101168
45. Barwick BG, Gupta VA, Vertino PM, Boise LH. Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. Front Immunol. 2019;10:1121. doi: 10.3389/fimmu.2019.01121. DOI: https://doi.org/10.3389/fimmu.2019.01121
46. Abdallah NH, Binder M, Rajkumar SV, et al. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022;12(1):21. doi: 10.1038/s41408-022-00611-x. DOI: https://doi.org/10.1038/s41408-022-00611-x
47. Chng WJ, Dispenzieri A, Chim CS, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269–77. doi: 10.1038/leu.2013.247. DOI: https://doi.org/10.1038/leu.2013.247
48. Goldschmidt H, Lokhorst HM, Mai EK, et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia. 2018;32(2):383–90. doi: 10.1038/leu.2017.211. DOI: https://doi.org/10.1038/leu.2017.211
49. Facon T, Moreau P, Špicka I, et al. Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long-term outcomes in the phase 3 IKEMA study. Hematol Oncol. 2024;42(2):e3258. doi: 10.1002/hon.3258. DOI: https://doi.org/10.1002/hon.3258
50. Harrison SJ, Perrot A, Alegre A, et al. Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. Br J Haematol. 2021;194(1):120–31. doi: 10.1111/bjh.17499. DOI: https://doi.org/10.1111/bjh.17499
51. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007;21(9):2035–42. doi: 10.1038/sj.leu.2404801. DOI: https://doi.org/10.1038/sj.leu.2404801
52. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29–37. doi: 10.1016/S1470-2045(09)70284-0. DOI: https://doi.org/10.1016/S1470-2045(09)70284-0
53. Banerjee R, Wang B, Anderson LD Jr, et al. Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians. Blood Cancer J. 2023;13(1):162. doi: 10.1038/s41408-023-00937-0. DOI: https://doi.org/10.1038/s41408-023-00937-0
54. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017;376(14):1311–20. doi: 10.1056/NEJMoa1611750. DOI: https://doi.org/10.1056/NEJMoa1611750
55. Perrot A, Lauwers-Cances V, Cazaubiel T, et al. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: Long-term follow-up analysis of the IFM 2009 trial. Blood. 2020;136(Suppl 1):39. doi: 10.1182/blood-2020-134538. DOI: https://doi.org/10.1182/blood-2020-134538
56. Richardson PG, Jacobus SJ, Weller EA, et al. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022;387(2):132–47. doi: 10.1056/NEJMoa2204925. DOI: https://doi.org/10.1056/NEJMoa2204925
57. Goldschmidt H, Mai EK, Bertsch U, et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 2022;9(11):e810–e821. doi: 10.1016/S2352-3026(22)00263-0. DOI: https://doi.org/10.1016/S2352-3026(22)00263-0
58. Mai EK, Bertsch U, Pozek E, et al. Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial. J Clin Oncol. 2024:JCO2402266. doi: 10.1200/JCO-24-02266. Epub ahead of print. DOI: https://doi.org/10.1200/JCO-24-02266
59. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024;390(4):301–13. doi: 10.1056/NEJMoa2312054. DOI: https://doi.org/10.1056/NEJMoa2312054
60. Rodríguez-Otero P, Moreau P, Dimopoulos MA, et al. Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial. 2024 ASCO Annual Meeting. J Clin Oncol. 2024:42(16_suppl): Abstract 7502. doi: 10.1200/JCO.2024.42.16_suppl.7502. DOI: https://doi.org/10.1200/JCO.2024.42.16_suppl.7502
61. Vaxman I, Muchtar E, Jacob E, et al. The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. Transplant Cell Ther. 2021;27(9):770.e1–770.e7. doi: 10.1016/j.jtct.2021.06.016. DOI: https://doi.org/10.1016/j.jtct.2021.06.016
62. Mollee P, Reynolds J, Janowski W, et al. Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03–16. Blood Adv. 2024;8(14):3721–30. doi: 10.1182/bloodadvances.2023012539. DOI: https://doi.org/10.1182/bloodadvances.2023012539
63. Войцеховский В.В., Есенина Т.В., Путинцев Д.В. и др. Терапия пациентов с множественной миеломой, осложненной хронической болезнью почек. Бюллетень физиологии и патологии дыхания. 2023;90:113–21. doi: 10.36604/1998-5029-2023-90-113-121. [Voytsekhovskiy V.V., Esenina T.V., Putintsev D.V., et al. Therapy for patients with multiple myeloma complicated by chronic kidney disease. Bulletin Physiology and Pathology of Respiration 2023;90:113–21. doi: 10.36604/1998-5029-2023-90-113-121. (In Russ)]
64. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349(26):2495–502. doi: 10.1056/NEJMoa032290. DOI: https://doi.org/10.1056/NEJMoa032290
65. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25(17):2434–41. doi: 10.1200/JCO.2006.10.2509. DOI: https://doi.org/10.1200/JCO.2006.10.2509
66. Stadtmauer EA, Pasquini MC, Blackwell B, et al. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. J Clin Oncol. 2019;37(7):589–97. doi: 10.1200/JCO.18.00685. DOI: https://doi.org/10.1200/JCO.18.00685
67. Pasquini MC, Wallace PK, Logan B, et al. Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival. J Clin Oncol. 2024;42(23):2757–68. doi: 10.1200/JCO.23.00934. DOI: https://doi.org/10.1200/JCO.23.00934
68. Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10(5):53. doi: 10.1038/s41408-020-0311-8. DOI: https://doi.org/10.1038/s41408-020-0311-8
69. Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. 2018;378(6):518–28. doi: 10.1056/NEJMoa1714678. DOI: https://doi.org/10.1056/NEJMoa1714678
70. Mateos MV, San-Miguel J, Cavo M, et al. Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study. Blood. 2022;140(Suppl 1):10157–9. doi: 10.1182/blood-2022-163347. DOI: https://doi.org/10.1182/blood-2022-163347
71. Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582–96. doi: 10.1016/S1470-2045(21)00466-6. DOI: https://doi.org/10.1016/S1470-2045(21)00466-6
72. Facon T, Kumar SK, Orlowski RZ, et al. Final Survival Analysis of Daratumumab Plus Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma: MAIA Study. EHA 2024 Hybrid Congress. HemaSphere. 2024;8(S1):P968.
73. Facon T, Dimopoulos MA, Leleu XP, et al. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024;391(17):1597–609. doi: 10.1056/NEJMoa2400712. DOI: https://doi.org/10.1056/NEJMoa2400712
74. Usmani SZ, Facon T, Hungria V, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat Med. 2025. doi: 10.1038/s41591-024-03485-7. Epub ahead of print. DOI: https://doi.org/10.1038/s41591-025-03581-2
75. Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068–74. doi: 10.1182/blood-2014-12-615187. DOI: https://doi.org/10.1182/blood-2014-12-615187
76. Семочкин С.В. CAR T-клеточная терапия множественной миеломы по материалам конгрессов ASH-2021 и ASCO-2022. Клиническая онкогематология. 2023;16(1):1–13. doi: 10.21320/2500-2139-2023-16-1-1-13. [Semochkin S.V. CAR-T Therapy of Multiple Myeloma, Based on the Congresses ASH-2021 and ASCO-2022. Clinical Oncohematology. 2023;16(1):1–13. doi: 10.21320/2500-2139-2023-16-1-1-13. (In Russ)] DOI: https://doi.org/10.21320/2500-2139-2023-16-1-1-13
77. San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023;389(4):335–47. doi: 10.1056/NEJMoa2303379. DOI: https://doi.org/10.1056/NEJMoa2303379
78. Costa LJ, Weisel KC, van de Donk NWCJ, et al. Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis. 2024 ASCO Annual Meeting. J Clin Oncol. 2024;42(16_suppl): Abstract 7504. doi: 10.1200/JCO.2024.42.16_suppl.7504. DOI: https://doi.org/10.1200/JCO.2024.42.16_suppl.7504
79. Ailawadhi S, Arnulf B, Patel K, et al. Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood. 2024;144(23):2389–401. doi: 10.1182/blood.2024024582. DOI: https://doi.org/10.1182/blood.2024024582
80. Jagannath S, Jackson CC, Schecter JM, et al. Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma. Expert Opin Biol Ther. 2024;24(5):339–50. doi: 10.1080/14712598.2024.2352591. DOI: https://doi.org/10.1080/14712598.2024.2352591
81. Jurgens E, Usmani SZ. SOHO State of the Art Updates and Next Questions: Will CAR-T Replace ASCT in NDMM. Clin Lymphoma Myeloma Leuk. 2024;24(5):277–84. doi: 10.1016/j.clml.2024.01.001. DOI: https://doi.org/10.1016/j.clml.2024.01.001
82. Verkleij CPM, O’Neill CA, Broekmans MEC, et al. T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple Myeloma. Clin Cancer Res. 2024;30(14):3006–22. doi: 10.1158/1078-0432.CCR-23-3333. DOI: https://doi.org/10.1158/1078-0432.CCR-23-3333
83. Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022;387(6):495–505. doi: 10.1056/NEJMoa2203478. DOI: https://doi.org/10.1056/NEJMoa2203478
84. Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022;387(24):2232–44. doi: 10.1056/NEJMoa2204591. DOI: https://doi.org/10.1056/NEJMoa2204591
85. Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259–67. doi: 10.1038/s41591-023-02528-9. DOI: https://doi.org/10.1038/s41591-023-02528-9
86. Popat R, Nooka A, van de Donk N, et al. Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2024;24(Suppl 2):S80. doi: 10.1016/S2152-2650(24)01970-0. DOI: https://doi.org/10.1016/S2152-2650(24)01970-0
87. Zamagni E, Silzle T, Špička I, et al. Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the MajesTEC-4/EMN30 Trial. Blood. 2024;144(Suppl 1):494. doi: 10.1182/blood-2024-205608. DOI: https://doi.org/10.1182/blood-2024-205608